Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Actively Recruiting
Led by Martin Schrappe · Updated on 2025-04-06
5000
Participants Needed
115
Research Sites
N/A
Total Duration
Researchers are studying acute lymphoblastic leukemia ALL in children and adolescents, recognizing it as a diverse disease with complex genetic features. The study aims to improve treatment by using more precise risk assessments and testing immunotherapy as an alternative to intensive chemotherapy, especially for patients at high risk of relapse. It also explores targeted therapy to overcome chemotherapy resistance and evaluates extended chemotherapy for T-cell ALL patients with slower treatment responses. The study divides patients into risk groups based on leukemia type, genetics, and treatment response, then tests different experimental treatments alongside standard chemotherapy. These include the proteasome inhibitor bortezomib during consolidation for high-risk B-cell ALL, immunotherapy with blinatumomab replacing intensive chemotherapy in high-risk patients, and blinatumomab for intermediate-risk patients. T-cell ALL patients receive extended consolidation chemotherapy to reduce relapse risk. Participants undergo a series of treatment phases including induction, consolidation, extra-compartment, reinduction, and maintenance therapy lasting up to two years after diagnosis. Treatments include various chemotherapy drugs and immunotherapy cycles depending on the assigned group. Researchers monitor outcomes such as event-free and disease-free survival over up to ten years, along with treatment toxicity and minimal residual disease response. Some high-risk patients may receive stem cell transplants or cranial irradiation as part of their treatment plan.
CONDITIONS
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
A
Anja Möricke, MD
L
Lile Bauer
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Martin Schrappe
Lead Sponsor
Deutsche Krebshilfe e.V., Bonn (Germany)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 weeks
Participants receive initial chemotherapy including prednisolone, vincristine, daunorubicin, pegaspargase, and intrathecal methotrexate as part of the induction phase.
Weekly visits during induction
Duration - 4 to 6 weeks
Participants undergo risk-stratified consolidation therapy which may include chemotherapy drugs like cyclophosphamide, cytarabine, 6-mercaptopurine, dexamethasone, vincristine, and pegaspargase. Experimental treatments such as bortezomib or extension of consolidation phase may be added depending on the participant's risk group and randomization.
Weekly visits during consolidation
Duration - 8 weeks
Participants receive additional chemotherapy with drugs including 6-mercaptopurine, high-dose methotrexate, and intrathecal methotrexate to target leukemic cells outside the bone marrow.
Regular visits during extra-compartment phase
Duration - 6 weeks
Participants receive reinduction chemotherapy with dexamethasone, vincristine, doxorubicin, pegaspargase, intrathecal methotrexate, cyclophosphamide, tioguanine, and cytarabine to further reduce leukemia burden.
Weekly visits during reinduction
Duration - 28 days per cycle, up to 2 cycles
Selected participants receive immunotherapy with blinatumomab as part of experimental treatment to improve disease-free survival, replacing some chemotherapy cycles depending on risk group and randomization.
1 to 2 visits per cycle (in-person)
Duration - Up to 2 years
Participants receive maintenance chemotherapy with 6-mercaptopurine and methotrexate for up to 2 years after initial diagnosis to maintain remission.
Monthly visits during maintenance
Duration - Variable, generally several weeks
Participants at high relapse risk may receive intensified chemotherapy blocks and additional treatments such as Myocet-FLA or allogeneic stem cell transplantation after consolidation, depending on response and risk stratification.
Multiple visits depending on treatment cycles
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
12
Have more questions? Get in touch with our team for quick support
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Özlem Tüfekçi, Melike Sezgin Evim, Adalet Meral Güneş...
https://pubmed.ncbi.nlm.nih.gov/35129146/Krzysztof Domka, Agnieszka Dąbkowska, Martyna Janowska...
https://pubmed.ncbi.nlm.nih.gov/38841802/Martin Schrappe
Lead Sponsor
Deutsche Krebshilfe e.V., Bonn (Germany)
Collaborating Sponsor